These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29187427)

  • 41. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
    Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen receptor and estrogen receptor variants in prostate and breast cancers.
    Valentín López JC; Lange CA; Dehm SM
    J Steroid Biochem Mol Biol; 2024 Jul; 241():106522. PubMed ID: 38641298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
    Bardia A; Gucalp A; DaCosta N; Gabrail N; Danso M; Ali H; Blackwell KL; Carey LA; Eisner JR; Baskin-Bey ES; Traina TA
    Breast Cancer Res Treat; 2018 Aug; 171(1):111-120. PubMed ID: 29744674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulating the Activity of Androgen Receptor for Treating Breast Cancer.
    You CP; Tsoi H; Man EPS; Leung MH; Khoo US
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
    Aakula A; Leivonen SK; Hintsanen P; Aittokallio T; Ceder Y; Børresen-Dale AL; Perälä M; Östling P; Kallioniemi O
    Mol Oncol; 2015 Aug; 9(7):1287-300. PubMed ID: 25907805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
    Hickey TE; Robinson JL; Carroll JS; Tilley WD
    Mol Endocrinol; 2012 Aug; 26(8):1252-67. PubMed ID: 22745190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
    Sharifi MN; O'Regan RM; Wisinski KB
    Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consideration of breast cancer subtype in targeting the androgen receptor.
    Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
    Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
    Sang M; Meng L; Ma C; Liu S; Sang M; Chang S; Liu F; Lian Y; Geng C
    Biomed Pharmacother; 2019 Mar; 111():169-177. PubMed ID: 30580238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
    Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
    Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly.
    Giovannelli P; Di Donato M; Auricchio F; Castoria G; Migliaccio A
    Sci Rep; 2019 Mar; 9(1):4490. PubMed ID: 30872694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes.
    Shukla N; Shah K; Rathore D; Soni K; Shah J; Vora H; Dave H
    Life Sci; 2024 Jul; 348():122697. PubMed ID: 38710280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
    Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
    Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
    Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
    Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen Receptor in Breast Cancer: From Bench to Bedside.
    Chen M; Yang Y; Xu K; Li L; Huang J; Qiu F
    Front Endocrinol (Lausanne); 2020; 11():573. PubMed ID: 32982970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
    Safarpour D; Tavassoli FA
    Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.
    Barton VN; Christenson JL; Gordon MA; Greene LI; Rogers TJ; Butterfield K; Babbs B; Spoelstra NS; D'Amato NC; Elias A; Richer JK
    Cancer Res; 2017 Jul; 77(13):3455-3466. PubMed ID: 28512248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.